Navigation Links
Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein

EDISON, N.J., April 21 /PRNewswire/ -- Nostrum, a privately-held company based in Edison, New Jersey, announced today that it has successfully completed its early, primate, proof-of-concept study for its novel thrombolytic clot-buster protein currently known as SMRX11. Nostrum's Symmetrix subsidiary, based in Singapore, is developing this therapeutic protein drug under Nostrum's license from the Institute of Microbial Technology, Chandigarh, India, which Nostrum obtained in July 2006.

SMRX11 is an engineered plasminogen activating hybrid protein produced by recombinant DNA technology. The hybrid protein activates plasminogen only in the presence of a blood clot. In the absence of the blood clot protein, Fibrin, SMRX11 displays no plasminogen activation. This unique product therefore potentially avoids the adverse reactions currently faced by thrombolytics in the market. Such adverse reactions include blood thinning and severe bleeding due to a significant degree of spontaneous plasminogen activation even in the absence of Fibrin. Moreover, SMRX11 protects fibrinogen levels in the blood, while dissolving the clot, and hence further lowering the risk of bleeding.

Nostrum recently successfully completed a proof-of-concept study in a non-human primate thrombolysis model that is expected to bear a close relationship with the future studies in humans. In this study, an appropriate dose of SMRX11 was administered as an intravenous bolus and successfully restored femoral arterial blood flow in cynomolgus monkeys following a stable thrombus formation. The animal model utilized has been previously validated on other, FDA approved thrombolytic products such as tPA. More recently, a similar study with SMRX11, which Nostrum conducted in a canine thrombolysis model, has confirmed the results observed in the primate study. "We have seen promising results in this primate model. We were clearly able to demonstrate the utility of SMRX11. Further studies will be conducted to show efficacy and safety of the product prior to our planned clinical studies in humans," said Yatindra Prashar, Ph.D., co-founder of Symmetrix. "We are excited about the possibility of treating millions of patients suffering from several cardiovascular conditions including Acute Myocardial Infarction, Ischemic Stroke, Peripheral Arterial Disease and Pulmonary Embolism in a cost efficient manner," said Nirmal Mulye, Ph.D., founder and President of Nostrum.

Nostrum will first pursue the clinical development and launch of SMRX11 in India followed by a worldwide launch. Nostrum's intellectual property as it relates to this technology is protected by patents obtained in the United States, Europe and India.

SOURCE Nostrum Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:12/1/2015)... 1, 2015   MabVax Therapeutics Holdings, Inc . ... it has filed an Investigational New Drug Application (IND) ... the Company,s lead fully human antibody product HuMab 5B1 ... plans to initiate the Phase I clinical trial early ... --> The planned Phase I trial will evaluate ...
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, Inc ... cycle solutions, today announced the company will showcase ... ChargeLink ® solution at the American ... Clinical Meeting . The new features are focused ... of monitoring and managing enterprise-wide pharmacy charges to ...
(Date:12/1/2015)... , Dec. 01, 2015 ... of the "Medical Alert Systems/Personal Emergency Response ... by Geography - Global Forecas" report to ... announced the addition of the "Medical Alert ... by End-User and by Geography - Global Forecas" ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... The Multiple System Atrophy Coalition has announced the launch of ... (MSA) research, timed today to coincide with Giving Tuesday 2015, a global day of ... to work and be productive, to do simple daily activities like walking to the ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, ... expansion of the company’s growing product line of food safety and seafood fraud ... Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):